Jul 25 |
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
Jul 15 |
Checkpoint, GC Cell to evaluate combo cancer therapy
|
Jul 15 |
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
|
Jul 2 |
Checkpoint resubmits FDA application for cosibelimab
|
Jul 2 |
Checkpoint Therapeutics Resubmits Biologics License Application for Cosibelimab, Launches $12 Million Direct Share Offering
|
Jul 2 |
Checkpoint Therapeutics looks to raise $12M through direct offering
|
Jul 2 |
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Jul 2 |
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
|
Jun 24 |
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
|
May 13 |
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|